title: Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.
abstract: Bendamustine is an increasingly used hybrid alkylating agent that is active in lymphoid neoplasias via a novel mechanism of action. There are some pending questions about its use in clinical practice because of its developmental features. A consensus panel of several leading Spanish hematologists with broad experience in the clinical use of bendamustine has established recommendations for the management and treatment of hematological patients with bendamustine based on available clinical data and the experience of the participants. These recommendations address the dose and treatment regimen for different clinical indications, the management of toxicity, and support therapy. This article contains the conclusions of this consensus panel, which are intended to serve as guidelines for the use of bendamustine.
authors.affiliation: Department of Hematology, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain.
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: Peñalver
authors.affiliation: Department of Hematology, Hospital Clinic, Barcelona, Spain.
authors.forename: Julio
authors.initials: J
authors.lastname: Delgado
authors.affiliation: Department of Hematology, Hospital Universitario de La Princesa, Madrid, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Loscertales
authors.affiliation: Department of Hematology, Complexo Hospitalario de Ourense, Ourense, Spain.
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: Sastre
authors.affiliation: Department of Hematology, Hospital Universitario San Carlos, Madrid, Spain.
authors.forename: Asunción
authors.initials: A
authors.lastname: Peña
authors.affiliation: Department of Hematology, Hospital Universitario Lozano Blesa, Zaragoza, Spain.
authors.forename: María Teresa
authors.initials: MT
authors.lastname: Olave
authors.affiliation: Department of Hematology, Hospital Universitario Gregorio Marañón, Madrid, Spain.
authors.forename: Santiago
authors.initials: S
authors.lastname: Osorio
authors.affiliation: Department of Hematology, MD Anderson Cancer Center, Madrid, Spain.
authors.forename: Adolfo
authors.initials: A
authors.lastname: de la Fuente
authors.affiliation: Department of Hematology, Hospital del Mar, Barcelona, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Salar
authors.affiliation: Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain.
authors.forename: Carlos
authors.initials: C
authors.lastname: Grande
authors.affiliation: Department of Hematology, Hospital Universitario Morales Messeguer, Murcia, Spain.
authors.forename: Elena
authors.initials: E
authors.lastname: Pérez Ceballos
authors.affiliation: Department of Hematology, Complexo Hospitalario de La Coruña, La Coruña, Spain.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Debén
authors.affiliation: Department of Hematology, Hospital Universitario Donostia, San Sebastián, Spain.
authors.forename: Asunción
authors.initials: A
authors.lastname: Echeveste
authors.affiliation: Department of Hematology, Hospital Virgen de la Salud, Toledo, Spain.
authors.forename: Felipe
authors.initials: F
authors.lastname: Casado
authors.affiliation: Department of Hematology, Hospital Universitario Doctor Peset, Valencia, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: de la Rubia
authors.affiliation: Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain.
authors.forename: Juan José
authors.initials: JJ
authors.lastname: Lahuerta
authors.affiliation: Department of Hematology, IBSAL-Hospital Universitario de Salamanca, Salamanca, Spain.
authors.forename: María Victoria
authors.initials: MV
authors.lastname: Mateos
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D056735:Autoimmune Lymphoproliferative Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D000069461:Bendamustine Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003245:Consensus Statements as Topic; D019468:Disease Management; D006801:Humans; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy*; D017410:Practice Guidelines as Topic
chemical_list: D018906:Antineoplastic Agents, Alkylating; D000069461:Bendamustine Hydrochloride
keywords: bendamustine; consensus; lymphoproliferative syndromes